Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 May 1;34(5):496-502.
doi: 10.1097/MEG.0000000000002342.

Randomized control trial on the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in reducing inflammatory markers in acute uncomplicated diverticulitis

Veronica Ojetti  1   2 , Angela Saviano  2 , Mattia Brigida  2 , Carmine Petruzziello  3 , Martina Caronna  2 , Gunawardena Gayani  2 , Francesco Franceschi  1   2
Affiliations
Randomized Controlled Trial

Randomized control trial on the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in reducing inflammatory markers in acute uncomplicated diverticulitis

Veronica Ojetti et al. Eur J Gastroenterol Hepatol. .

Abstract

Introduction: Recent guidelines suggest treating acute uncomplicated diverticulitis (AUD) without antibiotics. We tested the efficacy of Limosilactobacillus reuteri ATCC PTA 4659 in AUD. Primary outcome was the reduction of abdominal pain and inflammatory markers [C-reactive protein (C-RP) and calprotectin]. Secondary outcome was the reduction of hours of hospitalization.

Patients and methods: A double-blind, randomized controlled trial was conducted in 119 patients with AUD. The probiotic group (61 patients) was treated with fluids, bowel rest and L. reuteri/b.i.d. for 10 days. The placebo group (58 patients) was treated with the same therapy and placebo/b.i.d. for 10 days. All patients completed a daily visual analogue scale (VAS) for abdominal pain.

Results: Both groups showed a mean VAS score of 7 at enrolment and a reduction of 4 points after 3 days. C-RP value, after 72 h, decreased by 58.8% in the probiotic group and by only 40% in the placebo group (P < 0.05). Calprotectin levels, after 72 h, decreased by 17% in the probiotic group and by only 10.6% in the control group (P < 0.05). In the probiotic group, the hospitalization was done for 75.5 h compared to 83.5 in the placebo group.

Conclusions: The supplementation with L. reuteri 4659 together with bowel rest and fluids significantly reduced both blood and faecal inflammatory markers compared to the placebo group.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Fig. 1.
Fig. 1.
Study flowchart. IBD, inflammatory bowel disease.
Fig. 2.
Fig. 2.
Mean rating of abdominal pain as assessed by the visual analog scale (VAS) completed by subjects in groups A (Limosilactobacillus reuteri) and B (placebo) on Days 1, 3, 5, 7 and 10.
Fig. 3.
Fig. 3.
Mean value of C-reactive protein (C-RP, mg/L) determined at enrollment and at 72 h in subjects of groups A (Limosilactobacillus reuteri) and B (placebo).
Fig. 4.
Fig. 4.
Mean value of calprotectin determined at enrollment and at 72 h in subjects of groups A (Limosilactobacillus reuteri) and B (placebo).
See this image and copyright information in PMC

References

    1. Simpson J. Recent advances in diverticular disease. Curr Gastroenterol Rep 2004; 6: 417–422. - PubMed
    1. Colonic diverticular disease. Nat Rev Dis Primers 2020; 6: 21. - PubMed
    1. van Dijk ST, Rottier SJ, van Geloven AAW, Boermeester MA. Conservative treatment of acute colonic diverticulitis. Curr Infect Dis Rep 2017; 19: 44. - PMC - PubMed
    1. Blair NP, Germann E. Surgical management of acute sigmoid diverticulitis. Am J Surg 2002; 183: 525–528. - PubMed
    1. Salzman H, Lillie D. Diverticular disease: diagnosis and treatment. Am Fam Physician 2005; 72: 1229–1234. - PubMed

Publication types

Substances